Thursday, 15 October 2026European Markets

RETAIL ESTATES And SELECTIRENTE Have A High Dividend Yield And Return On Equity In The REIT - Retail Industry.

Loading stream...

(vianews) - retail estates (ret.br) is among this list of stock assets with the highest dividend rate and return on equity on the reit - retail industry.

financial asset price forward dividend yield return on equity
retail estates (ret.br) €68.00 7.41% 15.03%
selectirente (seler.pa) €88.00 4.57% 3.53%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. retail estates (ret.br)

7.41% forward dividend yield and 15.03% return on equity

the belgian public real estate investment trust retail estates nv is a niche player specialised in making out-of town retail properties located on the periphery of residential areas or along main access roads to urban centres available to users. retail estates nv acquires these real estate properties from third parties or builds and commercialises retail buildings for its own account. the buildings have useful areas ranging between 500 m² and 3,000 m². a typical retail building has an average area of 1,000 m² in belgium and 1,500 m² in the netherlands. as of 31 december 2023, retail estates nv has 1,025 rental units in its portfolio with a total retail area of 1,234,904 m², spread over belgium and the netherlands. the occupancy rate of the entire portfolio was 97.92% on 31 december 2023. the fair value of the consolidated real estate portfolio of retail estates nv as at 31 december 2023 is estimated at € 2,010.63 million by independent real estate experts. retail estates nv is listed on euronext brussels and euronext amsterdam and is registered as a public regulated real estate company.

earnings per share

as for profitability, retail estates has a trailing twelve months eps of €11.37.

pe ratio

retail estates has a trailing twelve months price to earnings ratio of 5.98. meaning, the purchaser of the share is investing €5.98 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.03%.

more news about retail estates.

2. selectirente (seler.pa)

4.57% forward dividend yield and 3.53% return on equity

selectirente is a public real estate fund managed by sofidy. it invests in city center and suburb commercial properties, which should be located close to shopping malls. it primarily acquires properties in france. as of march 29, 2019, selectirente operates as a subsidiary of tikehau capital.

earnings per share

as for profitability, selectirente has a trailing twelve months eps of €2.32.

pe ratio

selectirente has a trailing twelve months price to earnings ratio of 37.93. meaning, the purchaser of the share is investing €37.93 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.53%.

moving average

selectirente's value is above its 50-day moving average of €87.35 and below its 200-day moving average of €91.40.

yearly top and bottom value

selectirente's stock is valued at €88.00 at 12:40 est, way under its 52-week high of €102.00 and higher than its 52-week low of €85.00.

revenue growth

year-on-year quarterly revenue growth grew by 7.8%, now sitting on 36.37m for the twelve trailing months.

more news about selectirente.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com